The Feasibility and Effects of Low-load Blood-flow Restricted Exercise Following Spinal Cord Injury

Summary

Participation Requirements

Description

BACKGROUND Spinal cord injury (SCI) represents a major health concern; the World Health Organization estimates an incidence of 250,000 to 500,000 per year worldwide. On average in Denmark we register 130 new cases of SCI per year. SCI is a devastating condition, in which paresis/paralysis of the ske...

BACKGROUND Spinal cord injury (SCI) represents a major health concern; the World Health Organization estimates an incidence of 250,000 to 500,000 per year worldwide. On average in Denmark we register 130 new cases of SCI per year. SCI is a devastating condition, in which paresis/paralysis of the skeletal muscles below the injury site results in a partial or complete inability to walk, move and/or feel. Concurrent to functional disabilities, infections, lifestyle diseases such as cardiovascular diseases are frequent sequelae due to inactivity and overweight. Affecting primarily younger and previously healthy individuals traumatic SCI also profoundly impacts the mental wellbeing of the patients and also their next-of-kin; quality of life (QoL) suffers and subsequently the risk of suicide for patients with SCI increases by two to five times as compared to the background population. While a substantial effort is being put into the rehabilitation of individuals with SCI, large gaps in knowledge still exist on this area. Recovery of motor function is of high clinical priority as it is fundamental for improved ADL outcomes. While various strength training regimens have been shown to increase muscle strength in neurologically intact individuals using near-maximal voluntary effort contractions, few studies have demonstrated similar effects from strength training regimens in persons with SCI. Complications such as atrophy and easily fatigable neuromuscular system with various degrees of spasticity often make these kinds of regimes less practical and rewarding for rehabilitation. Therefore, the addition of low-load blood-flow restricted exercise (BFRE) may prove beneficial as a supplement to traditional rehabilitation. Notable, BFRE is found to increase muscle strength and induces skeletal muscle hypertrophy in healthy individuals. Typically, BFRE is performed as low-load strength training (20-30 % 1 Repetition Maximum (RM)) combined with concurrent partial occlusion of limb blood flow by means of pneumatic cuffs placed proximal at the limb, to restrit arterial inflow to the exercising muscle and preventing venous return. Based on existing scientific evidence and applying pre-exercisescreening for known risk factors such as vascular dysfunction (AD) or prior history of trombosis, BFRE is acknowledged as a safe exercise regime without serious side effects. Previously, the method has shown increased muscle strength and skeletal muscle hypertrophy in addition to improvements in gait and sit-to-stand performance in individuals with various diseases causing reduced mobility. The aim of this PhD project is to; To conduct a pilot study for investigate the safety and feasibility of low-load BFRE training in adults with SCI To conduct a RCT to investigate the effects of low-load blood-flow restricted exercise (BFRE) on physical function and neuromuscular recovery in individuals with SCI The hypotheses are as following; The BFRE training protocol will be safe and applicable to individuals with a spinal cord injury below Th7 Participants randomized to active BFRE treatment will exhibit greater increases in physical function and lower extremity muscle strength and muscle volume, respectively, than partici-pants receiving sham BFRE. Treatment effects will be documented using functional disability assessment tools combined with measurements of maximum voluntary isometric muscle strength, rapid force capacity (rate of force development: RFD) and cross sectional area of the trained muscles. Participants allocated to active BFRE will exhibit less neuropathic pain and reduced use of analgesic medication than participants receiving sham BFRE. This will be documented by standardized questionnaires and quantitative assessment methods. Feasibility Study (Study I) The feasibility study will be conducted by the applicant, Anette Bach Jønsson (ABJ). Consecutively, prior to the RCT, 3 individuals with a SCI will be recruited between 1/4 2020 - 31/7 2021 using the same recruitment strategy and in- and exclusions criteria as in the RCT. Additionally, 3 in-patients with sub-acute SCI (Time since injury > 1 month and > 1 year) will be recruited. The 6 patients will follow the same initial examination and training protocol as in the active BFRE group as described below. However, the training will be performed twice a week for 2 weeks. Outcome variables: The following outcome measurements will be performed at pre- and postintervention. Muscle testing Maximum, voluntary, isometric muscle strength that participants are able to exert on a portable knee dynamometer (S2P, Science to Practice, Ljubljana, Slovenia). Portable dynamometers are considered as valid and reliable instruments for measuring strength. Measurements of muscle torque (Nm) and Rate of Force Development (RFD, Nm/s) will be obtained. Blood samples Blood samples will be obtained pre (30 minutes) and post (0-60 minutes) the first and last training session (4 blood samples in total). In-house physicians or laboratory technician will be responsible for retrieving the blood samples. Markers of coagulation (fibrinogen and D-dimer), fibrinolysis [tissue plasminogen activator (tPA)] and inflammation [high sensitivity C-reactive protein (hsCRP)] will be analyzed. The blood samples will be destroyed immediately after analyzing. The results will be obtained through the electronic patient record. Feasibility Tolerance to the selected occlusion pressure and pain perception throughout training will be obtained by using the Numeric Rating Scale (NRS 0-11 point) and interview. Adherence to the planned training scheme will as well be recorded. Safety considerations Autonomic dysreflexia (AD) may be a potentially life-threatening condition for people with a high injury level (Th6 and above, Tetraplegia) and may be provoked by cutaneous stimulation such as pain. Therefore, patients at risk of AD will be excluded and the ISCOS Autonomic Standards Assesment Form will be fulfilled before and after completion. Eligibility for inclusion will be approved by specialist neurologist. Training sessions are coordinated with the physician-on-call. To ensure patient safety blood pressure and heart rate will be measured throughout training and will be closely monitored. In case of serious adverse events the MD on duty will be contacted immediately. During study I and II regular safety meetings in the research group will be scheduled. If serious adverse events occurs in study I, a reconsideration of the design of study II would be necessary (e.g. changes in BFR-dosage) and further pilot testing would be necessary. Randomized controlled trial (Study II) Methods Initial examination After inclusion, medical history, demographic and anthropometric data, spasticity level and the neurological level of SCI will be obtained. Spasticity level will be measures using Modified Ashworth Scale (MAS). Neurological level using the International Standards for Neurological Classification of SCI (ISNCSCI). Information about trauma date and reason, plan of standard care during hospitalization (physiotherapy, occupational therapy, hydrotherapy and other physical treatments/activities) will be obtained through the electronic patient record. Furthermore, functional disability assessment in addition to para-clinical tests will be conducted Intervention/Control Prior to the first training session, participants will be randomized to either active BFRE (n=14) or sham BFRE (n=14), while controlling for age and gender. BFR will be performed in the aBFRE group by use of pneumatic occlusion cuffs placed proximally on the thigh close to the inguinal fold, using an occlusion pressure corresponding to 40 % of seated arterial occlusion pressure (AOP). The individual AOP will be documented at baseline using doppler ultrasound (Siemens ACUSON S2000TM). Previous studies have shown that this pressure level can promote significant muscle adaptations to a similar degree and are associated with significantly less discomfort than higher occlusion pressures. The occlusion pressure of the participants in sham BFRE group will be 10mmHg. Subjects from both groups will participate in 45 minutes of low-intensity BFRE (30-40% 1RM) of the lower extremities twice/week for 8 weeks, consisting of 5 minutes light warm-up of low-intensity cycling followed by 4 sets (30x15x15x15 repetitions, 45 sec pause between sets) of seated leg extension and leg curl with BFR. A 3 minutes pause is allowed between exercises where the cuff will be deflated. Blood pressure will be measured with a temporal resolution of approx. 5 minutes throughout training. Data analysis Within-group changes from baseline to follow-up will be analyzed using paired parametric or nonpar-ametric methods. Between-group differences will be compared as unpaired data using a parametric or nonparametric methods. The type 1 level of significance is set at 0.05. The results will be analyzed according to the intention-to-treat principle. According to sample-size calculation with an 80 % power and 5 % level of significance a difference of 20 % on MVC between the active and sham BFR groups are possible to detect with 24 participants. A total of 28 participants will be recruited to take a 20 % dropout rate into account. A difference of 20 % on MVC is expected as a realistic suggestion as a minimal clinical important difference. Practical framework This PhD project has received permission from SCIWDK. The initial examination and tests at baseline and follow-up will be conducted at SCIWDK's laboratory by the applicant, Anette Bach Jønsson (ABJ). She is an experienced physiotherapist. Training sessions will be guided and supervised by in-house physiotherapists and ABJ. Ethical considerations: The study has been approved by The Danish Scientific Ethics Commission (Ref No. 1-10-72-290-18), and by Data Protection Agency (Datatilsynet, Ref No. 1-16-02-640-18) and has been reported to Clinicaltrials.gov. Economy: Not described here

Tracking Information